Effect of HIV protease inhibitors on New World Leishmania

Parasitology International

Volumn 61, Issue 4, 2012, Pages 538-544

  Demarchi, Izabel G ^a   Silveira, Thaís G V ^a   Ferreira, Izabel C P ^a   Lonardoni, Maria V C ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

Antiretroviral; Cutaneous leishmaniasis; HAART; HIV protease inhibitors; Leishmania

Indexed keywords

ATAZANAVIR; INDINAVIR; RITONAVIR;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; IC 50; LEISHMANIASIS; LYMPH NODE; MOUSE; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; PROMASTIGOTE; SPLEEN;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV PROTEASE INHIBITORS; INDINAVIR; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; MICE; OLIGOPEPTIDES; PYRIDINES; RITONAVIR;

AMBYSTOMA TIGRINUM STEBBENSI VIRUS; LEISHMANIA AMAZONENSIS; LEISHMANIA BRAZILIENSIS; MUS;

EID: 84865958936     PISSN: 13835769     EISSN: 18730329     Source Type: Journal    
DOI: 10.1016/j.parint.2012.04.006     Document Type: Article

References (55)

1. WHO, World Health Organization Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. progress report 2009 2009, WHO Publications, Geneva.
2. Borges A.S., Machado A.A., Ferreira M.S., de Castro Figueiredo J.F., Silva G.F., Cimerman S., et al. Concurrent leishmaniasis and human immunodeficiency virus (HIV) infection: a study of four cases. Revista da Sociedade Brasileira de Medicina Tropical 1999, 32:713-719.
3. Brasil. Ministério da Saúde. Manual de recomendaçes para diagnostico, tratamento e acompanhamento de pacientes com a coinfecção Leishmania-HIV/Ministério da Saúde, Secretaria de Vigilância em Saúde Departamento de Vigilância Epidemiológica 2011, Ministério da Saúde, Brasília.
4. Vianna G. Sobre uma espécie de Leishmania. Brasil-Médico 1912, 25:411.
5. Silveira F.T., Lainson R., Gomes C.M.C., Laurenti M.D., Corbett C.E. Immunopathogenic competences of Leishmania (V.) braziliensis and Leishmania (L.) amazonensis in American cutaneous leishmaniasis. Parasite Immunology 2009, 31:423-431.
6. Murray H.W. Kala-azar as an AIDS-related opportunistic infection. AIDS Patient Care and STDs 1999, 13:459-465.
7. Amato V.S., Nicodemo A.C., Amato J.G., Boulos M., Neto V.A. Mucocutaneous leishmaniasis associated with HIV infection treated successfully with liposomal amphotericin B (AmBisome). Journal of Antimicrobial Chemotherapy 2000, 46:341-342.
8. Amato V.S., Rabello A., Rotondo-Silva A., Kono A., Maldonado T.P., Alves I.C., et al. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Tropica 2004, 92:127-132.
9. Brow M., Noursadeghj M., Boyle J., Davidson R.N. Successful lipossomal amphotericin B treatment of Leishmania braziliensis cutaneos leishmaniasis. British Journal of Dermatology 2005, 153:203-205.
10. Olivier M., Badaró R., Medrano F.J., Moreno J. The pathogenesis of Leishmania-HIV co-infections cellular and immunological mechanisms. Annals of Tropical Medicine and Parasitology 2003, 97:79-98.
11. Pozio E. Highly active antiretroviral therapy and opportunistic protozoan infections. Parassitologia 2004, 46:83-89.
12. Abbenante G., Failie D.P. Protease inhibitors in the clinic. Medicinal Chemistry 2005, 1:71-104.
13. West M.L., Fairlie D.P. Targeting HIV-1 protease: a test of drug-design methodologies. Trends in Pharmacological Sciences 1995, 16:67-75.
14. Savoia D., Allice T., Tovo P.A. Antileishmanial activity of HIV protease inhibitors. International Journal of Antimicrobial Agents 2005, 26:92-94.
15. Trudel N., Garg R., Messier N., Sundar S., Oullette M., Tremblay M.J. Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors. Journal of Infectious Diseases 2008, 198:1292-1299.
16. White R.E., Powell D.J., Berry C. HIV proteinase inhibitors target the Ddi1-like protein of Leishmania parasites. The FASEB Journal 2011, 25:1729-1736.
17. De Diego J.L., Katz J.M., Marshall P., Gutiérrez B., Manning J.E., Nussenzweig V. The ubiquitin-proteasome pathway plays an essential role in proteolysis during Trypanosoma cruzi remodeling. Biochemistry 2001, 40:1053-1062.
18. Shaw M.K., He C.Y., Roos D.S., Tilney L.G. Proteasome inhibitors block intracellular growth and replication of Toxoplasma gondii. Parasitology 2000, 121:35-47.
19. Deuroin F., Santillana-Hayat M. Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro. Antimicrobial Agents and Chemotherapy 2000, 44:2575-2577.
20. Gantt S.M., Myung J.M., Briones M.R., Li W.D., Corey E.J., Omura S., et al. Proteasome inhibitors block development of Plasmodium spp. Antimicrobial Agents and Chemotherapy 1998, 42:2731-2738.
21. Parikh S., Gut J., Istvan E., Goldberg D.E., Havlir D.V., Rosenthal P.J. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrobial Agents and Chemotherapy 2005, 49:2983-2985.
22. Skinner-Adams S., Mccarthy J.S., Gardiner D.L., Hilton P.M., Andrews K.T. Antiretrovirals as antimalarial agents. Journal of Infectious Diseases 2004, 190:1998-2000.
23. Dunn L.A., Andrews K.T., Mccarthy J.S., Wright J.M., Skinner-Adams T.S., Upcroft P., et al. The activity of protease inhibitors against Giardia duodenalis and metronidazole-resistant Trichomonas vaginalis. International Journal of Antimicrobial Agents 2007, 29:98-102.
24. Mele R., Morales M.A.G., Tozini F., Pozio E. Indinavir reduces Crypstosporidium parvum infection in both in vitro and in vivo models. International Journal of Parasitology 2003, 33:757-764.
25. Alfieri S.C., Shaw E., Zilberfarb V., Rabinovitch M. Leishmania amazonensis: involvement of cysteine proteinases in the killing of isolated amastigotes by l-leucine methyl ester. Experimental Parasitology 1989, 68:423-431.
26. Christensen C.B., Jorgensen L., Jensen A.T., Gasim S., Chen M., Kharazmi A., et al. Molecular characterization of a Leishmania donovani cDNA clone with similarity to human 20S proteasoma alfa-type subunit. Biochimica et Biophysica Acta 2000, 1500:77-87.
27. Pozio E., Morales M.A.G. The impact of HIV-protease inhibitors on opportunistic parasites. Trends in Parasitology 2005, 21:53-58.
28. Rafati S., Nakhaee A., Taheri T., Ghashghaii A., Salmanian A.H., Jimenez M., et al. Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine. Experimental Parasitology 2003, 103:143-151.
29. Robertson C.D. The Leishmania mexicana proteasome. Molecular and Biochemical Parasitology 1999, 103:49-60.
30. Somanna A., Mundodi V., Gedamu L. Functional analysis of cathepsin B-like cysteine protease from Leishmania donovani complex. Journal of Biological Chemistry 2002, 277:25305-25312.
31. Valdivieso E., Dagger F., Rascón A. Leishmania mexicana: identification and characterization of an aspartyl proteinase activity. Experimental Parasitology 2007, 116:77-82.
32. Kumar P., Lodge R., Trudel N., Ouellet M., Ouellette M., Tremblay M.J. Nelfinavir, an HIV-1 protease inhibitor, induce oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes. PLoS Neglected Tropical Diseases 2010, 4:e642.
33. Alves C.R., Corte-Real S., Bourguignon S.C., Chaves C.S., Saraiva E.M. Leishmania amazonensis: early proteinase activities during promastigote-amastigote differentiation in vitro. Experimental Parasitology 2005, 109:38-48.
34. Valdivieso E., Rangel A., Moreno J., Saugar J.M., Cañavate C., Alvar J., et al. Effects of HIV aspartyl-proteinase inhibitors on Leishmania sp. Experimental Parasitology 2010, 126:557-563.
35. Santos L.O., Marinho F.A., Altoé E.F., Vitório B.S., Alves C.R., Britto C., et al. HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis. PLoS One 2009, 4:e4918.
36. Lindoso J.A., Barbosa R.N., Posada-Vergara M.P., Duarte M.I., Oyafuso L.K., Amato V.S., et al. Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World. British Journal of Dermatology 2009, 160:311-318.
37. Ferreira I.C.P., Lonardoni M.V.C., Machado G.M.C., Leon L.L., Gobbi Filho L., Pinto L.H., et al. Anti-leishmanial activity of alkaloidal extract from Aspidosperma ramiflorum. Memórias do Instituto Oswaldo Cruz 2004, 99:325-327.
38. Gomes de C., Alegrio L.V., de Lima M.E., Leon L.L., Araújo C.A. Synthetic derivatives of curcumin and their activity against Leishmania amazonensis. Arzneimittel-Forschung Drug Research 2002, 52:120-124.
39. Lonardoni M.V.C., Russo M., Jancar S. Essential role of platelet-activating factor in control of Leishmania (Leishmania) amazonensis infection. Infection and Immunity 2000, 68:6355-6361.
40. Neal R.A., Hale C. A comparative study of susceptibility of inbred and outbred mouse strains compared with hamster to infection with New World cutaneous leishmaniases. Parasitology 1983, 87:7-13.
41. Samuelson J., Lerner E., Tesh R., Titus R. A mouse model of Leishmania braziliensis braziliensis infection produced by coinjection with sand fly saliva. The Journal of Experimental Medicine 1991, 173:49-54.
42. Honda P.A., Ferreira I.C.P., Cortez D.A.G., Amado C.A., Silveira T.G., Brenzan M.A. Efficacy of components from leaves of Calophyllum brasiliense against Leishmania (Leishmania) amazonensis. Phytomedicine 2010, 17:333-338.
43. Buffet P.A., Sulahian A., Garin Y.J.F., Nassar N., Deuroin F. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrobial Agents and Chemotherapy 1995, 39:2167-2168.
44. Korting H.C., Schaller M., Eder G., Hamm G., Böhmer U., Hube B. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrobial Agents and Chemotherapy 1999, 43:2038-2042.
45. Courret N., Frehel C., Prina E., Lang T., Antoine J.C. Kinetics of the intracellular differentiation of Leishmania amazonensis and internalization of host MHC molecules by the intermediate parasite stages. Parasitology 2001, 122:263-279.
46. Galvao-Quintao L., Alfieri S.C., Ryter A., Rabinovitch M. Intracellular differentiation of Leishmania amazonensis promastigotes to amastigotes: presence of megasomes, cysteine proteinase activity and susceptibility to leucine-methyl ester. Parasitology 1990, 101:7-13.
47. Salvati L., Mattu M., Colasanti M., Scalone A., Venturini G., Gradoni L., et al. NO donors inhibit Leishmania infantum cysteine proteinase activity. Biochimica et Biophysica Acta 2001, 1545:357-366.
48. Blanco M.T., Hurtado C., Pérez-Giraldo C., Móran F.J., González-Velasco C., Gómez-García A.C. Effect of ritonavir and saquinavir on Candida albicans growth rate in vitro activity of aspartyl proteinases. Medical Mycology 2003, 41:167-170.
49. Cassone A., Tacconelli E., De Bernardis F., Tumbarello M., Torosantucci A., Chiani P., et al. Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. Journal of Infectious Diseases 2002, 185:188-195.
50. Turco S.J., Spath G.F., Beverley S.M. Is lipophosphoglycan a virulence factor? A surprising diversity between Leishmania species. Trends in Parasitology 2001, 17:223-226.
51. Assis R.R., Ibraim I.C., Noronha F.S., Turco S.J., Soares R.P. Glycoinositol phospholipids from Leishmania braziliensis and L. infantum: modulation of innate immune system and variations in carbohydrate structure. PLoS Neglected Tropical Diseases 2012, 6:1543.
52. Mukhopadhyay R., Madhubala R. Effects of bis(benzyl)polyamine analogs on Leishmania donovani promastigotes. Experimental Parasitology 1995, 81:39-46.
53. Andrews K.T., Fairlie D.P., Madala P.K., Ray J., Wyatt D.M., Hilton P.M., et al. Potencies of human immunodeficiency virus protease inhibitors in vitro against murine malaria. Antimicrobial Agents and Chemotherapy 2006, 50:639-648.
54. De La Rosa R., Pineda J.A., Delgado J., Macías J., Morillas F., Mira J.A., et al. Incidence and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. Journal of Clinical Microbiology 2002, 40:762-767.
55. Del Giudice P., Mary-Krause M., Pradier C., Grabar S., Dellamonica P., Marty P., et al. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. Journal of Infectious Diseases 2002, 1861:1366-1370.